BUZZ-ASX-listed Aroa Biosurgery rises as H1 loss narrows, upbeat H2 outlook

Reuters2024-11-26
BUZZ-ASX-listed Aroa Biosurgery rises as H1 loss narrows, upbeat H2 outlook

** Shares of Aroa Biosurgery ARX.AX rise as much as 3.85% to A$0.675, their highest level since Nov. 13

** NZ's medical products maker posts H1 FY25 loss after tax attributable of NZ$3.3 mln ($1.93 mln), compared to NZ$6.3 mln from a year before

** H1 FY25 revenue from ordinary activities - product sales NZ$39.1 mln, up 25% from a year before

** Co anticipates H2 FY25 total revenue of NZ$43-$50 million

** Expects H2 FY25 normalised EBITDA profit of NZ$4-8 mln

** However stock has fallen 21.7% YTD, as of last close

($1 = 1.7112 New Zealand dollars)

(Reporting by Sherin Sunny in Bengaluru)

((Sherin.Sunny@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment